Niagen Bioscience, Inc. (NAGE) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Niagen Bioscience, Inc. stock $3.85, price $2.07, upside +86.0%, quality 71 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $1.19 – $14.41 · fair‑value band $2.43 – $4.67 · the $2.07 price screens below the $3.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Niagen Bioscience in your weekly email
Every Wednesday you see whether Niagen Bioscience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.
Show moreShow less
It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products.
In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name.
The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers.
The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Stock analysis
Niagen Bioscience, Inc. (NAGE) currently trades at $2.07, while our model-based Fair Value estimate is $3.85, implying the stock looks roughly 46% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $6.37 per share, and 20 of the 24 models we run sit above the $2.07 price.
Bear case: the Asset-Based group reads lowest at $0.8500, and 4 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $2.43 (bear) to $4.67 (bull), the price of $2.07 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Consumer Defensive sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Niagen Bioscience, Inc. reported revenue of $129M in FY2025 versus $67.4M in FY2021, a compound +17.7%/yr. Reported net income was $17.4M in FY2025.
Key figures
Market cap $171M Micro · P/E ratio 17.3 · P/S ratio 2.32 · EPS (TTM) $0.1200 · Net margin 13.4% · Return on equity 21.8% · Return on assets (EBIT) −13.3% (5-year average) · Operating margin 2.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).
What moves the price
The share trades about 71% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at 86%, NAGE screens cheaper than that median.
Fair Value models
Bear$2.43Fair Value $3.85Bull$4.67
Price $2.07 · Upside +86.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.1029 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, no officer or director bought or sold shares on the open market.
BuyOzan PamirChief Financial Officer6,685 shares at $6.82$45,616Nov 14, 2025
Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+29.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Start year 2020 (pandemic). Over 10 years: +21.9% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−33.5% (2020) → 11.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +0.5% a year for the price and +8.4% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Compare Niagen Bioscience, Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 625 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside+86.0% · Top 25%
Profitability
Return on equity (12 months)21.8% · Top 25%
Return on assets16.3% · Top 25%
Net margin (12 months)12.4% · Top 25%
Operating margin (12 months)2.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)−4.3% · Bottom 25%
Valuation Multiplesvs Packaged Foods median · lower = cheaper
P/E (12 months)17.3× · Pricier than median
P/B2.23× · Pricier than median
P/S (12 months)1.32× · Pricier than median
Price / free cash flow (fiscal year)13.0× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Niagen Bioscience, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/NAGE
Frequently asked questions
Is Niagen Bioscience, Inc. (NAGE) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $3.85 versus a price of $2.07, about +86% upside (undervalued).
What is the fair value of NAGE?
Our model-based fair value for Niagen Bioscience, Inc. is $3.85 (as of Nov 6, 2026), built from audited fundamentals. The current price: $2.07.
What is the quality score of NAGE?
Niagen Bioscience, Inc. has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Niagen Bioscience, Inc. (NAGE)?
Our model-based price target is the fair value of $3.85 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $2.43, optimistic scenario $4.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Niagen Bioscience, Inc. stock forecast for 2026?
Our models put fair value at $3.85, about +86% upside versus a price of $2.07 (undervalued). Cautious scenario $2.43, optimistic scenario $4.67. The calculation is refreshed regularly with new filings.
What is the revenue of Niagen Bioscience, Inc. (NAGE)?
Niagen Bioscience, Inc. reported trailing-twelve-month revenue of about $129M (latest available figure, as of Nov 6, 2026).
What growth is priced into Niagen Bioscience, Inc. (NAGE)?
For today's price to be fair in a discounted-cash-flow model, Niagen Bioscience, Inc. would have to grow free cash flow by +2.9 % per year for five years (discount rate 15.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.9 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of NAGE use?
Our models discount Niagen Bioscience, Inc. at 15.2 %: a base by market capitalisation (micro), damped by beta 2.08, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Niagen Bioscience, Inc. that is +2.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (15.2 %) and the same formula as our fair value.
How much growth has Niagen Bioscience, Inc. (NAGE) delivered so far?
Over the past 5 years revenue at Niagen Bioscience, Inc. grew +16.9 % a year. The price currently implies free-cash-flow growth of +2.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Niagen Bioscience, Inc. (NAGE) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Niagen Bioscience, Inc. (+2.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Niagen Bioscience, Inc. (NAGE)?
The free-cash-flow yield on the price is 7.70 %: that much free cash flow Niagen Bioscience, Inc. produces per unit of market value. When it exceeds the discount rate of our models (15.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Niagen Bioscience, Inc. (NAGE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Niagen Bioscience, Inc. it is $3.85 per share (as of Nov 6, 2026), against a price of $2.07. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Niagen Bioscience, Inc. stock overvalued or undervalued in 2026?
As of Nov 6, 2026, NAGE trades below its calculated fair value: price $2.07, fair value $3.85, a gap of about +86% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NAGE?
No. The price is what the market pays today ($2.07); the fair value is what the company's own numbers justify ($3.85). For Niagen Bioscience, Inc. the two are $1.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is Niagen Bioscience, Inc. worth?
The market values Niagen Bioscience, Inc. at about $171M (market capitalisation, as of Nov 6, 2026). Per share that is $2.07; our models calculate a fair value of $3.85 per share.
What do the bullish and bearish scenarios say about NAGE?
Our models span a range for Niagen Bioscience, Inc.: cautious scenario $2.43, base $3.85, optimistic $4.67 per share (as of Nov 6, 2026, price $2.07). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NAGE?
Niagen Bioscience, Inc. trades at a price-to-earnings ratio of 17.3 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.85 is built from several models across several years. Other multiples: P/B 2.2, P/S 1.3, EV/EBITDA 11.1.
How solid is the balance sheet of Niagen Bioscience, Inc. (NAGE)?
Balance-sheet figures for Niagen Bioscience, Inc. (as of Nov 6, 2026): return on equity 21.8%. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is NAGE from its 52-week high?
Niagen Bioscience, Inc. trades at $2.07, about 71% below its 52-week high of $7.18 and at the low of $2.07 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $3.85 is for.
Which stocks are comparable to Niagen Bioscience, Inc.?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Niagen Bioscience, Inc. stock attractive at the current price?
The data as of Nov 6, 2026: price $2.07, calculated fair value $3.85 (+86%), Quality Score 71/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NAGE calculated?
We run Niagen Bioscience, Inc. through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $3.85 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Niagen Bioscience, Inc. currently trades 46% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Niagen Bioscience, Inc. (NAGE)?
The closing price on Nov 6, 2026 was $2.07. Our model-based fair value is $3.85, about +86% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Niagen Bioscience, Inc. right now?
The price is below even our cautious bear case ($2.43). The market is more pessimistic than our downside scenario. Solid quality (71/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($2.43 to $4.67) leaves room in how you read the outcome.
Key figures of Niagen Bioscience, Inc.
How large is the market capitalisation of Niagen Bioscience, Inc. (NAGE)?
The market capitalisation of Niagen Bioscience, Inc. is $171M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Niagen Bioscience, Inc. (NAGE)?
The price-to-sales ratio of Niagen Bioscience, Inc. is 2.32 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Niagen Bioscience, Inc. (NAGE)?
Earnings per share at Niagen Bioscience, Inc. are $0.1200 (price ÷ EPS = P/E 17.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Niagen Bioscience, Inc. (NAGE)?
The net margin of Niagen Bioscience, Inc. is 13.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Niagen Bioscience, Inc. (NAGE)?
The return on equity (ROE) of Niagen Bioscience, Inc. is 21.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Niagen Bioscience, Inc. (NAGE)?
On an EBIT basis the return on assets of Niagen Bioscience, Inc. is −13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Niagen Bioscience, Inc. (NAGE)?
The operating margin of Niagen Bioscience, Inc. is 2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Niagen Bioscience, Inc. (NAGE)?
Revenue at Niagen Bioscience, Inc. is growing −4.3% versus a year earlier (3y avg +21.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Niagen Bioscience, Inc. (NAGE)?
Earnings per share at Niagen Bioscience, Inc. are growing −75.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Niagen Bioscience, Inc. (NAGE) hold?
Niagen Bioscience, Inc. holds more cash than debt, $62.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Niagen Bioscience, Inc. in the live analysis
One click puts Niagen Bioscience, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026